A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD

Buitelaar, Jan K.; Danckaerts, Marina; Gillberg, Christopher; Zuddas, Alessandro; Becker, Katja; Bouvard, Manuel; Fagan, Jenny; Gádoros, Júlia; Harpin, Valerie; Hazell, Philip; Johnson, Mats; Lerman‐Sagie, Tally; Soutullo, César; Wolańczyk, Tomasz; Zeiner, Pål; Fouche, D.S.; Krikke-Workel, Judith; Zhang, Shuyu; Michelson, David

doi:10.1007/s00787-004-0401-3

Cited by 58 publications

(36 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the duration of atomoxetine treatment in this first study was set at 8 weeks, our findings were comparable to results from similar studies worldwide (Michelson et al 2001;Spencer et al 2001;Biederman et al 2002;Michelson et al 2002;Spencer et al 2002;Buitelaar et al 2004;Kelsey et al 2004), atomoxetine was found to be safe and well tolerated up to 1.8 mg=kg per day.…”

Section: Discussionsupporting

confidence: 90%

“…Information from teachers has extended these findings to the school setting and has shown similar outcomes for both efficacy and safety (Weiss et al 2005). Also, in most trials, the rates of discontinuation due to adverse events were less than 5% (Michelson et al 2001;Spencer et al 2001;Biederman et al 2002;Michelson et al 2002;Spencer et al 2002;Buitelaar et al 2004;Kelsey et al 2004), indicating that atomoxetine is safe and well tolerated in children and adolescents with ADHD. Prior to this study, no placebo-controlled studies had been conducted in Japanese patients.…”

Section: Introductionmentioning

confidence: 80%

See 1 more Smart Citation

A Randomized, Double-Blind, Placebo-Controlled Study of Atomoxetine in Japanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Takahashi

Takita

Yamazaki

et al. 2009

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 80%

A Randomized, Double-Blind, Placebo-Controlled Study of Atomoxetine in Japanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Takahashi

Takita

Yamazaki

et al. 2009

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Improvement in physical functioning was not reported in the other studies of the effects of amphetamine 10,11 or a non-stimulant on HRQOL. [11][12][13][14][15] Improvement to physical motor functioning in our populations was to be expected, considering the demonstrated effects of MPH on fine motor functioning needed for autonomic and creative functions, and handwriting in children with ADHD/DCD. 16,17 Unfortunately, the effect of MPH alone is not large enough to equalize differences with controls in all HRQOL-domains.…”

Section: Discussionmentioning

confidence: 99%

“…It is striking that so few studies evaluated HRQOL and clinical outcome after medication for ADHD, including two stimulant (amphetamine) 10,11 and five nonstimulant (atomoxetine) studies [11][12][13][14][15] showing improvement in HRQOL psychosocial domains during treatment. As stimulants have emerged as the first-line effective therapy to treat ADHD, and as methylphenidate (MPH) has a positive effect both on behavioural ADHD symptoms and motor symptoms (handwriting), 16,17 medication with MPH seems to be the first choice in ADHD/DCD.…”

mentioning

confidence: 99%

Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD

Flapper

Schoemaker

2008

Develop Med Child Neuro

View full text Add to dashboard Cite

Measurement of health-related quality of life (HRQOL) in attention-deficit-hyperactivity disorder (ADHD) gives a more complete picture of day-to-day functioning and treatment effects than behavioural rating alone. The aim of this pilot study was to investigate the impact of the combined diagnoses of developmental coordination disorder (DCD) and ADHD on HRQOL, and the effectiveness of methylphenidate (MPH) on HRQOL. HRQOL was established using the Dutch-Child-AZL-TNO-Quality-of-Life (DUX-25) and the TNO-AZL-ChildQuality-of-Life (TACQOL) questionnaires, completed by children and parents. HRQOL of these children was compared with that of 23 age-and sex-matched healthy controls. Twentythree children (21 males, two females; mean age 8y 6mo, [SD 3mo] range 7y-10y 8mo) with ADHD/DCD entered a 4-week, open-label MPH study, after MPH-sensitivity was established, in a double-blind, placebo-controlled trial. In these children's self-and proxy reports, impact of both DCD and ADHD was reflected in lower general well-being (self and proxy report p=0.001) due to lower functioning in motor (self p=0.026; proxy 0.001), autonomic (self p<0.001; proxy p=0.047), cognitive (self p=0.001; proxy p=0.01), and social (self and proxy p<0.001) domains. HRQOL scores improved in 18 children receiving MPH (p=0.001) versus controls. The ADHD/DCD group also demonstrated a significant improvement in ADHD symptoms (p<0.001) and motor functioning (p<0.001). Additional motor therapy will still be needed in about half of the children with ADHD/DCD receiving MPH, within multimodal treatment including educational and psychosocial assistance.Attention-deficit-hyperactivity disorder (ADHD) 1 and developmental coordination disorder (DCD) 2 are two developmental disorders present in 5% of children, of whom co-occurrence is present in 30 to 50%. These disorders have a severe impact on daily activities, as symptoms of persistent inattention, impulsivity, and hyperactivity, or motor coordination dysfunction, cause substantial interference in daily life (Diagnostic and Statistical Manual of Mental Disorders, 4th edn; DSM-IV). Children with both ADHD and DCD experience problems into adulthood (60%) more often than those with ADHD only. 3 Therefore, there is an urgent need to recognize DCD in ADHD populations and to measure healthrelated quality of life (HRQOL) in these children.HRQOL has been advocated as a measure of the level of interference in day-to-day functioning. It is a multidimensional construct, defined as the impact of health status (including disease and treatment) on physical, psychological (adjustment and self-esteem), and social functioning (family and peer relationships). 4 To acquire a more complete picture of treatment effects, measurement of HRQOL can be complementary to ratings of the reduction of behavioural symptoms in ADHD and motor symptoms in DCD.There have been several studies on HRQOL in ADHD. A recent review of 10 studies showed that ADHD affects psychosocial health and has a significant impact on family life and activities. 5 So f...

show abstract

“…Clinically significant effects are only seen after 4 to 6 weeks. It has been shown to be effective in a number of clinical trials [64,65]. The medication was well tolerated, with discontinuation rates due to adverse events of less than 5% in pediatric studies.…”

Section: Atomoxetinementioning

confidence: 98%

Long-term treatment of children and adolescents with attention-deficit/ hyperactivity disorder (ADHD)

Hechtman

2006

Curr Psychiatry Rep

View full text Add to dashboard Cite

Only 7% to 50% of children with attention-deficit/hyperactivity disorder actually are treated. Of those who begin treatment, only 18% to 50% persist in the treatment for any length of time (eg, 2 to 3 years). Thus, available data on effects of long-term medication and psychosocial treatment are sparse and problematic. This article reviews available data on long-term effects of medication (stimulant and nonstimulant) and psychosocial treatment.

show abstract

A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD

Abstract: These open-label data, gathered in an international setting, add to our knowledge of the value of atomoxetine in treating ADHD symptoms, as well as its safety and tolerability.

Cited by 58 publications

References 23 publications

A Randomized, Double-Blind, Placebo-Controlled Study of Atomoxetine in Japanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

A Randomized, Double-Blind, Placebo-Controlled Study of Atomoxetine in Japanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD

Long-term treatment of children and adolescents with attention-deficit/ hyperactivity disorder (ADHD)

Contact Info

Product

Resources

About